Ionis Pharmaceuticals Stock Forecast, Price & News

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IONS stock has decreased by 4.5% and is now trading at $46.95.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Ionis Pharmaceuticals.

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Ionis Pharmaceuticals.

Ionis Pharmaceuticals will be holding an earnings conference call on Wednesday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.05. The company had revenue of $146 million for the quarter, compared to analyst estimates of $148.87 million. Ionis Pharmaceuticals had a return on equity of 10.27% and a net margin of 13.81%. The company's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.01) EPS.
View Ionis Pharmaceuticals' earnings history.

15 Wall Street analysts have issued 12-month price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $50.00 to $91.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $68.92 in the next twelve months. This suggests a possible upside of 46.8% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.42%), Dowling & Yahnke LLC (0.41%), Sicart Associates LLC (0.30%), BLB&B Advisors LLC (0.13%), Peregrine Capital Management LLC (0.13%) and DAVENPORT & Co LLC (0.09%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Dowling & Yahnke LLC, Nisa Investment Advisors LLC, Pinnacle Associates Ltd., Peregrine Capital Management LLC, WINTON GROUP Ltd, DAVENPORT & Co LLC, Arden Trust Co, and Standard Life Aberdeen plc. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals.

IONS stock was purchased by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Assenagon Asset Management S.A., Riggs Asset Managment Co. Inc., IBM Retirement Fund, NuWave Investment Management LLC, IFM Investors Pty Ltd, XTX Markets LLC, and NEXT Financial Group Inc.
View insider buying and selling activity for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $46.95.

Ionis Pharmaceuticals has a market capitalization of $6.56 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 817 workers across the globe.

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected]